Skip to main content
Erschienen in: Supportive Care in Cancer 1/2006

01.01.2006 | Original Article

No pain relief from morphine?

Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients

verfasst von: Julia Riley, Joy R. Ross, Dag Rutter, Athol U. Wells, Katherine Goller, Ron du Bois, Ken Welsh

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

The aims of this study were (1) to prospectively evaluate the clinical benefits of switching from morphine to an alternative opioid, using oxycodone as first-line alternative opioid, in patients with cancer, (2) to evaluate the consistency of the clinical decision for the need to switch by comparing two hospital sites, and (3) to evaluate whether there were objective predictors that would help identify morphine non-responders who require switching to an alternative opioid and from this to construct a clinical model to predict the need to switch.

Patients and methods

One hundred eighty-six palliative care patients were prospectively recruited from two hospital sites. Responders were patients treated with morphine for more than 4 weeks with good analgesia and minimal side effects. Non-responders (switchers) were patients who had either uncontrolled pain or unacceptable side effects on morphine and therefore required an alternative opioid. The differentiation between responders and switchers was made clinically and later confirmed by objective parameters.

Results

In this prospective study 74% (138/186) had a good response to morphine (responders). One patient was lost to follow up. Twenty-five percent (47/186) did not respond to morphine. These non-responders were switched to alternative opioids (switchers). Furthermore, of 186 patients, 37 achieved a successful outcome when switched to oxycodone and an additional 4 were well controlled when switched to more than one alternative opioid. Overall successful pain control with minimal side effects was achieved in 96% (179/186) of patients. There were no significant differences in the need to switch between the two hospital sites.

Conclusions

This study has shown that proactive clinical identification and management of patients that require opioid switching is reproducible in different clinical settings and significantly improves pain control. Further studies are required to develop and test the predictive model.
Literatur
1.
Zurück zum Zitat World Health Organisation (1996) Cancer pain relief, 2nd edn. World Health Organisation, Geneva World Health Organisation (1996) Cancer pain relief, 2nd edn. World Health Organisation, Geneva
2.
Zurück zum Zitat Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P et al (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19(11):2898–2904PubMed Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P et al (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19(11):2898–2904PubMed
3.
Zurück zum Zitat de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10(5):378–384CrossRefPubMed de Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10(5):378–384CrossRefPubMed
4.
Zurück zum Zitat Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8(2):63–67CrossRefPubMed Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8(2):63–67CrossRefPubMed
5.
Zurück zum Zitat Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73(2):151–157CrossRefPubMed Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73(2):151–157CrossRefPubMed
6.
Zurück zum Zitat Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T (1990) Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67(4):322–328 Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T (1990) Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 67(4):322–328
7.
Zurück zum Zitat Saarialho-Kere U, Mattila MJ, Seppala T (1989) Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65(4):252–257PubMed Saarialho-Kere U, Mattila MJ, Seppala T (1989) Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65(4):252–257PubMed
8.
Zurück zum Zitat Gagnon B, Bielech M, Watanabe S, Walker P, Hanson J, Bruera E (1999) The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer 7:265–270 Gagnon B, Bielech M, Watanabe S, Walker P, Hanson J, Bruera E (1999) The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer 7:265–270
9.
Zurück zum Zitat Kalso E, Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47:639–646 Kalso E, Vainio A (1990) Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 47:639–646
10.
Zurück zum Zitat Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T (1991) Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 35:642–646PubMed Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T (1991) Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 35:642–646PubMed
11.
Zurück zum Zitat Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86(9):1856–1866CrossRefPubMed Mercadante S (1999) Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86(9):1856–1866CrossRefPubMed
12.
Zurück zum Zitat Riley J, Ross JR, Rutter D, Shah S, Gwilliam B, Wells AU et al (2004) A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain. Palliat Med 18(1):19–24CrossRefPubMed Riley J, Ross JR, Rutter D, Shah S, Gwilliam B, Wells AU et al (2004) A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain. Palliat Med 18(1):19–24CrossRefPubMed
13.
Zurück zum Zitat D’Honneur G, Gilton A, Sandouk P, Scherrmann M, Duvaldestin P (1994) Plasma and cerebrospinal fluid concentrations of morphine and morphine gluronides after oral morphine. The influence of renal failure. Anesthesiology 81:87–93PubMed D’Honneur G, Gilton A, Sandouk P, Scherrmann M, Duvaldestin P (1994) Plasma and cerebrospinal fluid concentrations of morphine and morphine gluronides after oral morphine. The influence of renal failure. Anesthesiology 81:87–93PubMed
14.
Zurück zum Zitat Farrell A, Rich A (2000) Analgesic use in patients with renal failure. Eur J Palliat Care 7(6):201–205 Farrell A, Rich A (2000) Analgesic use in patients with renal failure. Eur J Palliat Care 7(6):201–205
15.
Zurück zum Zitat Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J (1990) The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 29(3):289–297PubMed Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J (1990) The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 29(3):289–297PubMed
16.
Zurück zum Zitat Lesage P, Portenoy RK (1999) Trends in cancer pain management. Cancer Control 6(2):136–145PubMed Lesage P, Portenoy RK (1999) Trends in cancer pain management. Cancer Control 6(2):136–145PubMed
17.
Zurück zum Zitat Regan J, Yarnold J, Jones PW, Cooke NT (1991) Palliation and life quality in lung cancer; how good are clinicians at judging treatment outcome? Br J Cancer 64(2):396–400 Regan J, Yarnold J, Jones PW, Cooke NT (1991) Palliation and life quality in lung cancer; how good are clinicians at judging treatment outcome? Br J Cancer 64(2):396–400
18.
Zurück zum Zitat Quigley C (2004) Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 3:CD004847 Quigley C (2004) Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 3:CD004847
19.
Zurück zum Zitat Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M (1995) Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10(4):287–291CrossRefPubMed Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M (1995) Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 10(4):287–291CrossRefPubMed
20.
Zurück zum Zitat Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B et al (1995) Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76(7):1283–1293PubMed Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B et al (1995) Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76(7):1283–1293PubMed
21.
Zurück zum Zitat Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64(6):603–611 Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64(6):603–611
Metadaten
Titel
No pain relief from morphine?
Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients
verfasst von
Julia Riley
Joy R. Ross
Dag Rutter
Athol U. Wells
Katherine Goller
Ron du Bois
Ken Welsh
Publikationsdatum
01.01.2006
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0843-2

Weitere Artikel der Ausgabe 1/2006

Supportive Care in Cancer 1/2006 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.